The funding round was led by Hatteras Venture Partners and Noro-Moseley Partners with participation from FS Healthcare LLC and Excelerate Health Ventures.
Elligo did not provide any comment on the Series A round, though some of the initial investors, including Shumway Capital, did also participate in the second round, the company said.
The Series B funds will be used to expand the scale of the business “after a very successful 2016 and 2017,” said John Potthoff, Elligo CEO.
“In addition, we will be supporting the implementation of technology solutions with support of Saama,” he told us.
Elligo earlier this month announced a partnership with Saama Technologies through which the companies will build new technology platforms to help sponsors achieve their objectives faster, Potthoff told us at the time.
The platform will leverage Saama’s Life Science Analytics Cloud to support patient population identification based on clinical trial eligibility requirements.